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Abstract In this report we explored the e¡ects of proteasome
inhibitors (MG132, aLLN, lactacystin and MG262) on interleu-
kin-8 (IL-8) induction. In HEK293 cells, proteasome inhibitors
could concentration-dependently increase IL-8 promoter and ac-
tivator protein-1 (AP-1) activities, but inhibited nuclear factor
(NF)-UB activation induced by cytokines. The stimulating ef-
fects on IL-8 promoter and AP-1 were reduced by N-acetylcys-
teine, glutathione, diphenyleneiodonium, rotenone and antimycin
A. Fluorescent analysis using 2P,7P-dichlorodihydro£uorescin di-
acetate further con¢rmed the abilities of proteasome inhibitors
to induce reactive oxygen species (ROS) production. These re-
sults suggest that ROS production by proteasome inhibitors
leads to AP-1 activation, which in the absence of NF-UB acti-
vation still transactivates IL-8 gene expression. 7 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Proteasomes are large multi-subunit protease complexes,
which are localized in the nucleus and cytosol, and selectively
degrade intracellular proteins. Accumulating evidence has
strengthened the crucial roles of proteasomes in the degrada-
tion of many proteins involved in cell cycling, proliferation,
and apoptosis [1]. A vast majority of short-lived, normal pro-
teins and misfolded, abnormal proteins are degraded by this
system. A protein marked for degradation is ¢rst covalently
attached to multiple molecules of ubiquitin, and is then es-
corted for rapid hydrolysis by proteasomes. Proteins which
undergo regulation by this mechanism include cyclins, Bcl-2
[2], p53 [3], c-Fos [4], c-Jun, nuclear factor (NF)-UB precursor,
JAKs [5], STATs, HIF-1K, retinoid X receptor [6], retinoic
acid receptor [7], peroxisome proliferator-activated receptor
Q [8], and estrogen receptor [9]. It is thus conceivable that a
great variety of cellular regulatory mechanisms, examples
ranging from the progression of the cell cycle to the pathways
controlling signal transduction and metabolism, are controlled
by the ubiquitin/proteasome system.
NF-UB and activator protein-1 (AP-1) are two major tran-
scriptional systems distinctly regulated by proteasomes. In the
NF-UB signaling pathway, the inhibitory protein of NF-UB,
IUB, can be degraded by the proteasome. This results in the
up-regulation of the expression of many NF-UB-dependent
genes. Viewing the crucial roles of NF-UB in in£ammation
and promoting cell survival, the inhibition of IUB degradation
and NF-UB activation by proteasome inhibitors has set up a
novel strategy for anti-in£ammatory and anti-cancer drug de-
velopment [10,11]. However, in the aspect of regulating the
AP-1 signaling cascade, the proteasome inhibitor MG132, on
the contrary, can activate c-Jun N-terminal kinase (JNK) ac-
tivation and induce some downstream responses. AP-1-depen-
dent cell apoptosis [12], neurite outgrowth [13], and transcrip-
tional gene expression of monocyte chemoattractant protein 1,
stromelysin, mitogen-activated protein kinase, phosphatase 1,
and cyclooxygenase-2 all have been reported for MG132 ac-
tion [14,15]. Although MG132 prevention of c-Fos and/or
c-Jun degradation might account for AP-1 activation, the
rapid JNK activation by MG132 is another alternative path-
way [15]. However, the mechanism responsible for JNK-re-
lated AP-1 activation and the action speci¢city for other pro-
teasome inhibitors are still uninvestigated.
Since proteasome inhibitors have been considered as ther-
apeutic drugs for the treatment of in£ammation, it is interest-
ing to explore their actions on interleukin (IL)-8 expression.
IL-8 is a CXC chemotactic factor for neutrophils, T cells and
basophils [16], and has been implicated in several in£am-
matory diseases [17]. IL-8 secretion is primarily regulated at
the transcription level, and its promoter region contains the
DNA binding sites for NF-UB and AP-1 [18^20]. Since the
involvement of both transcription factors for IL-8 induction is
stimulus-speci¢c [19^22], it is interesting to explore the mech-
anisms responsible for IL-8 induction by proteasome inhibi-
tors.
2. Materials and methods
2.1. Reagents and plasmids
Dulbecco’s modi¢ed Eagle’s medium (DMEM), fetal bovine serum
(FBS), penicillin, and streptomycin were obtained from Gibco BRL
(Grand Island, NY, USA). aLLN, lactacystin, MG132, MG262, N-
acetylcysteine (NAC) and glutathione (GSH) were purchased form
Calbiochem (Darmstadt, Germany). H2O2, diphenyleneiodonium
(DPI), rotenone and antimycin A were obtained from Sigma Aldrich
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(St. Louis, MO, USA). All materials for SDS^PAGE were obtained
from Bio-Rad Laboratories (Hercules, CA, USA). Luciferase expres-
sion vectors containing the 5P-£anking region of the IL-8 gene (3133
to 350) and speci¢c mutants of NF-UB, AP-1 and nuclear factor-
interleukin-6 (NF-IL-6) were provided by Dr. N. Mukaida (Kanaza-
wa University, Ishikawa, Japan). AP-1-Luc construct was provided by
Dr. Guy Haegeman (University of Gent-VIB, Gent, Belgium). pGL2-
ELAM-Luc (UB-Luc) under the control of one NF-UB binding site
was constructed.
2.2. Cell culture
Human embryonic kidney (HEK) 293 cells, obtained from Ameri-
can Type Culture Collection (Manassas, VA, USA), were grown at
37‡C in 5% CO2 using DMEM containing 10% FBS, 100 U/ml pen-
icillin and 100 Wg/ml streptomycin.
2.3. Transfection and reporter gene assay
For transfection assays, 5U105 HEK293 cells were seeded into six-
well plates. Cells were transfected on the following day by the calcium
phosphate precipitation method. Premix DNA with 33.4 Wl 0.1UTE
bu¡er, 12.6 Wl 1 M CaCl2 in a tube for each well, then mix slowly with
46 Wl 2UHanks’ balanced salt solution in 25 s. Incubate the mixture
for 25 min at room temperature, and add into each well. After 24 h
incubation, transfection was complete, and cells were incubated with
the indicated concentrations of proteasome inhibitors. After another
24 h incubation, the media were removed, and the cells were washed
once with cold phosphate-bu¡ered saline. To prepare lysates, 100 Wl
of reporter lysis bu¡er (Promega) was added to each well, cells were
scraped from dishes. Collect the supernatant after centrifugation at
13 000 rpm for 30 s. Aliquots of cell lysates (5 Wl) containing equal
amounts of protein (10^20 Wg) were placed into the wells of an opa-
que black 96-well microplate. An equal volume of luciferase substrate
(Promega) was added to all samples, and the luminescence was mea-
sured in a microplate luminometer (Meriden, CT, USA). The lucifer-
ase activity value was normalized to transfection e⁄ciency monitored
by the cotransfected L-galactosidase expression vector (pCR3lacZ;
Pharmacia, Sweden), and is presented as the percentage of luciferase
activity measured in the presence of each proteasome inhibitor relative
to the activity of control cells with no stimulation.
2.4. Flow cytometry for ROS formation
2P,7P-Dichlorodihydro£uorescin diacetate (DCFH-DA) was used as
an indicator for the formation of intracellular reactive oxygen species
(ROS). Cells were pretreated with DCFH-DA (50 WM) for 30 min,
and then indicated concentrations of proteasome inhibitors were
added for di¡erent time periods. Once ROS was generated, the
DCFH oxidation product, DCF £uorescence can be detected by
£ow cytometer (FACScan, Becton Dickinson). The £uorescence was
assessed by counts of FL1-H, and the mean value would represent the
ability of a chemical compound to induce ROS formation.
2.5. Statistical evaluation
Values are expressed as the meanTS.E.M. of at least three experi-
ments, which were performed in duplicate. Analysis of variance was
used to assess the statistical signi¢cance of the di¡erences, and a
P value of less than 0.05 was considered statistically signi¢cant.
3. Results
3.1. Proteasome inhibitors increased IL-8 and AP-1 luciferase
activity
To determine the gene regulatory e¡ect of proteasome in-
hibitors on IL-8 expression, we performed reporter gene
assays to test four proteasome inhibitors, MG132, aLLN,
lactacystin, and MG262. As shown in Fig. 1, these four
proteasome inhibitors increased IL-8 promoter activity in a
concentration-dependent manner. MG262 was the most po-
tent proteasome inhibitor to achieve IL-8 stimulation within
0.1 nM^1 WM. MG132 and lactacystin, on the other hand,
exhibited a moderate and comparable potency within 0.1^50
WM. Among the proteasome inhibitors tested, aLLN was the
weakest one to stimulate IL-8 response. The stimulation e⁄-
cacy at the highest concentration of these inhibitors examined,
1 WM for MG262, 50 WM for MG132 and lactacystin, was
around a 12^14-fold increase, while that for 50 WM of aLLN
was about eight-fold. At these concentrations examined, no
cytotoxicity was seen. However, increasing the concentrations
of MG132, lactacystin and aLLN to 100 WM resulted in cy-
totoxicity within 24 h, as assessed from the MTT assay (data
not shown).
Consistent with previous studies showing that MG132 can
cause AP-1 activation [12^15], all four proteasome inhibitors
possessed similar e¡ects to stimulate AP-1 luciferase activity.
Moreover, the relative potency and e⁄cacy for AP-1 stimula-
tion were correlated to IL-8 gene induction (Fig. 2).
Fig. 1. Four proteasome inhibitors increased IL-8 promoter activity
in HEK293 cells in a concentration-dependent manner. HEK293
cells were co-transfected with wild-type cDNA construct of IL-8
promoter (0.5 Wg) and L-gal-lacZ (0.5 Wg). Twenty-four hours later,
0.01^50 WM of MG132, aLLN, lactacystin, and 0.1 nM^1 WM
MG262 were added for another 24 h, and then cell lysates were pre-
pared and IL-8 promoter activity was assessed by measurement of
luciferase activity. Results were normalized for transfection e⁄ciency
with L-gal-lacZ. Each data point represents the meanTS.E.M. of at
least three independent experiments, which were performed in dupli-
cate.
Fig. 2. Four proteasome inhibitors increased AP-1 reporter activity.
HEK293 cells were co-transfected with wild-type AP-1 promoter
(0.5 Wg) and L-gal-lacZ (0.5 Wg). Twenty-four hours later, 0.01^
50 WM of MG132, aLLN, lactacystin, and 0.1 nM^1 WM of MG262
were added for 24 h, and then cell lysates were prepared for report-
er activity assay. Results were normalized for transfection e⁄ciency
with L-gal-lacZ. Each data point represents the meanTS.E.M. of at
least three independent experiments, which were performed in dupli-
cate.
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3.2. Proteasome inhibitors inhibited cytokine-induced UB
reporter activity
To verify the inhibitory action of these proteasome inhib-
itors on NF-UB transcription, the UB-luciferase reporter gene
assay was carried out. The results revealed that while UB lu-
ciferase activity in basal condition is not altered by MG132,
aLLN, lactacystin, or MG262, its stimulation by two potent
NF-UB inducing cytokines, IL-1L (10 ng/ml) and tumor ne-
crosis factor K (TNF-K) (50 ng/ml), was antagonized by the
presence of proteasome inhibitors (data not shown). The IC50
values against cytokine-induced NF-UB activation were 0.1^
0.3 WM for MG132, 1 WM for aLLN and lactacystin, and 1^3
nM for MG262.
3.3. ROS-dependent e¡ects of proteasome inhibitors
Since several reports have indicated AP-1 transcription fac-
tor as a target of ROS [20,23,24], we next wanted to address
the role of ROS in the action of proteasome inhibitors. An-
other reason to address this issue is the recent ¢nding that
lactacystin can lead to signi¢cant oxidative damage in NT-2
Fig. 3. Antioxidants reduced the stimulatory e¡ects of proteasome
inhibitors. HEK293 cells were co-transfected with either IL-8 pro-
moter (0.5 Wg) (A) or AP-1 promoter (0.5 Wg) (B) together with
L-gal-lacZ (0.5 Wg). Twenty-four hours later, cells were pretreated
with NAC (3 or 10 mM) or GSH (5 or 30 mM) for 30 min, and
then indicated concentrations of MG132 (10 WM), aLLN (10 WM),
lactacystin (10 WM) and MG262 (0.1 WM) were added for another
24 h, followed by luciferase assay. Results were normalized for
transfection e⁄ciency with L-gal-lacZ. Each data point represents
the meanTS.E.M. of at least three independent experiments, which
were performed in duplicate. *P6 0.05 as compared to the control
response without NAC or GSH treatment.
Fig. 4. Proteasome inhibitors induced ROS production. HEK293
cells loaded with 50 WM DCFH-DA for 30 min were treated with
vehicle or proteasome inhibitors (10 WM MG132, 10 WM aLLN, 10
WM lactacystin, and 0.1 WM MG262) in the dark for di¡erent peri-
ods. Then £uorescent intensity was measured by £ow cytometry.
Each data point represents the meanTS.E.M. of three to ¢ve inde-
pendent experiments.
Fig. 5. NADPH oxidase and mitochondrial inhibitors reduced the
stimulatory e¡ects of proteasome inhibitors. HEK 293 cells were co-
transfected with either IL-8 promoter (0.5 Wg) (A) or AP-1 pro-
moter (0.5 Wg) (B) together with L-gal-lacZ (0.5 Wg). Twenty-four
hours later, cells were treated with DPI (10 WM), rotenone (3 WM),
or antimycin A (1 WM) for 30 min, followed by MG132 (10 WM),
aLLN (10 WM), lactacystin (10 WM), or MG262 (0.1 WM). After in-
cubation for 24 h, luciferase assay as normalized by transfection ef-
¢ciency with L-gal-lacZ was determined. Each data point represents
the meanTS.E.M. of at least three independent experiments, which
were performed in duplicate. *P6 0.05 as compared to the control
response without inhibitor treatment.
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and SK-N-MC cell lines [25]. Fig. 3 shows that when the
antioxidant NAC (3 or 10 mM) or GSH (5 or 30 mM) was
pretreated for 15 min, the increased extents of IL-8 and AP-1
reporter activities caused by proteasome inhibitors were mark-
edly attenuated. This result suggested the involvement of ROS
as intermediators in the signaling pathway induced by protea-
some inhibitors. To verify this suggestion, we used the £uo-
rescent agent DCFH-DA to measure the intracellular content
of ROS. When examining the concentrations of these protea-
some inhibitors that induced maximal and comparable stim-
ulation on IL-8 and AP-1 (10 WM for MG132, aLLN and
lactacystin, and 0.1 WM for MG262), the results shown in
Fig. 4 indicated the time-dependent increases of intracellular
ROS following exposure to proteasome inhibitors. Within 3 h
incubation, the e¡ects of MG132, lactacystin and MG262 on
ROS production exhibited biphasic features, which peaked at
5 min, declined gradually and re-induced around 1 h. The
e⁄cacy in terms of the rapid stimulation at 5 min is
MG262s lactacystinsMG132, aLLN, while that occurring
at 1 h is MG132sMG262, lactacystins aLLN. When exam-
ining MG132, aLLN and lactacystin at 0.1 and 1 WM, and
MG262 at 0.01 WM, the ROS production at 5 min was also
increased by 40^80% (data not shown).
To further determine the source(s) of proteasome inhibitors
to generate ROS, we examined DPI, the NADPH oxidase
inhibitor; rotenone, a potent inhibitor of mitochondria com-
plex I; and antimycin A, an inhibitor of mitochondria elec-
tron transport. As shown in Fig. 5, DPI, rotenone, and anti-
mycin A all reduced proteasome inhibitor-stimulated
luciferase activities of IL-8 promoter and AP-1.
4. Discussion
Previous studies have demonstrated that IL-8 gene tran-
scription is regulated mainly by NF-UB and AP-1 [18^20].
Although NF-UB has been reported to be essential for IL-8
induction by IL-1L and TNF-K [19,20], NF-UB-independent,
but AP-1-dependent regulation has been demonstrated in
H2O2 action [20^22]. Following observation of the increased
IL-8 promoter activity by proteasome inhibitors, we therefore
examined the roles of NF-UB and AP-1. Reporter gene assay
clearly demonstrated that proteasome inhibitors could reduce
NF-UB activation, especially in the presence of cytokines IL-
1L and TNF-K, which were demonstrated to trigger NF-UB
activation through IUB kinase-dependent phosphorylation,
ubiquitination and degradation of IUB [26,27]. In this study,
blockade of proteasome-dependent IUB degradation and NF-
UB activation by proteasome inhibitors was shown. In addi-
tion, the potency order for NF-UB inhibition seen in this cell
system (MG262EMG132, lactacystin, aLLN) correlates
quite well with previous ¢ndings in terms of Ki values for in
vitro proteasome inhibition and IC50 values for NF-UB inhi-
bition [25,28^31].
In contrast to NF-UB inhibition, AP-1 is stimulated by
proteasome inhibitors, and this action accounts for the gene
induction of IL-8. Pharmacological approaches using antiox-
idants and selective inhibitors of ROS production further sug-
gest ROS as a key player for AP-1 signaling. In this aspect,
mitogen-activated protein kinases, the upstream essential reg-
ulators of AP-1 activation, are signaling targets of ROS [32^
37]. Moreover, since inhibitors of NADPH oxidase and mito-
chondrial respiratory chain reaction can markedly diminish
the stimulatory e¡ects of proteasome inhibitors, ROS produc-
tion from both NADPH oxidase and mitochondria are sug-
gested to be involved. Consistent with this point, we for the
¢rst time demonstrate that intracellular ROS level is increased
by four proteasome inhibitors at concentration ranges to in-
duce AP-1 and IL-8 promoter activation, and support a pre-
vious study showing the ability of lactacystin (1^25 WM) to
induce oxidative protein damage [25]. However, since antiox-
idants and inhibitors of ROS production did not abolish the
increased IL-8 promoter and AP-1 activities, whether any
other intermediate molecules and/or action mechanisms, be-
sides ROS-related signaling, contribute to the actions of pro-
teasome inhibitors needs to be investigated.
In summary, we demonstrate that ROS production possibly
from NADPH oxidase and mitochondria mediates the major
signaling pathway for proteasome inhibitors to stimulate IL-8
gene expression. ROS-dependent AP-1 transcriptional activa-
tion is su⁄cient to induce IL-8 response in the absence of NF-
UB activation.
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